Eli Lilly and Company (LLY)
Why Eli Lilly Stock Climbed to a Record High Today
Eli Lilly's shareholders are in store for even more gains, according to a respected investment bank. The drugmaker is poised to profit from the rapid growth of the global obesity treatment market.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly Price Prediction: The Case for Double-Digit Upside
Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware of the landmark shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo Nordisk.
Why Eli Lilly Gained 7% On Friday
Eli Lilly saw its biggest gain of 7% in yesterday's trading session since early February, when it jumped 10% on the release of 2025 results. While LLY's gains outstripped peers, it was hardly alone in advancing, with stocks like JNJ and ABBV up too, reflecting a broader momentum for the soft healthcare sector YTD. The company's own developments in segments like oncology and neuroscience set LLY apart from the healthcare pack, though, as they highlight its potential beyond the weight loss market.
Eli Lilly shares rise after EU panel backs expanded use of Jaypirca
Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The positive opinion covers patients regardless of prior treatment with Bruton tyrosine kinase (BTK) inhibitors and marks a step toward broader availability of the drug in the European Union.
